Navigation Links
ThreeWire Expands Presence in the Pharmaceutical Arena
Date:5/27/2008

Utilizes extensive experience in medical device industry to benefit

pharmaceutical clinical trial recruitment efforts

MINNEAPOLIS, May 27 /PRNewswire/ -- Leading clinical trial recruitment and direct-to-patient marketing firm ThreeWire has strengthened the pharmaceutical side of its business with the addition of two directors of business development and a commitment to leveraging differentiators unique to the medical device industry on behalf of pharmaceutical industry clients.

According to ThreeWire CEO and President, Mark Summers, "In the world of medical device clinical research studies, you have to motivate patients to agree to have a device surgically implanted in their body. Add to that a restrictive protocol, and you are now recruiting from a narrow, hard-to-reach patient population that must be prepared to undergo a highly invasive surgical procedure. Success depends on a system that targets only the most qualified patients and keeps them engaged throughout the healthcare continuum. It is that experience we are using to drive enrollment for pharmaceutical clinical trials."

In order to help pharmaceutical companies in their patient recruitment efforts, ThreeWire has hired Janine Katz and Shannon McDonnell. Katz is a business development professional with over ten years of experience in clinical trial patient recruitment and public relations programs in the pharmaceutical and healthcare industries. McDonnell brings leadership skills in business development in the healthcare field, including two years focused solely on clinical trial recruitment. Both will report to Jim Suddendorf, Senior Vice President, Business Development and Client Services.

"As the regulatory bar is being raised and greater numbers of patients are being required for trial completion, the challenge of patient recruitment is being elevated," adds Suddendorf. "Successful enrollment solutions depend on a systematic marketing approach, which is
'/>"/>

SOURCE ThreeWire
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse
2. DuPont Expands Animal Health Solutions Business in Asia
3. Hospira Expands Board of Directors
4. Sidec AB Expands Into New Offices
5. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
6. SAFC Hitech(TM) Expands Sheboygan Facility With State-of-the-Art Manufacturing Cleanroom
7. Quintiles Consulting Business Expands
8. REVISED: BrainCells Inc. Expands Series B Financing to $50 Million
9. BrainCells Inc. Expands Series B Financing to $50 Million
10. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
11. SeqWright Expands Next Generation Lineup with the Addition of 454s GS FLX(TM) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... Israel , September 2, 2015 ... TASE: BOLT) ("BioLight" or the "Company"), a firm ... in ophthalmology and cancer diagnostics, announced today that ... of glaucoma will be delivered at the Ophthalmology ... the European Society of Cataract & Refractive Surgeons ...
(Date:9/2/2015)... NJ (PRWEB) , ... September 02, 2015 , ... ... Technical Services Staff members will be attending Pharma Ed Resources upcoming educational ... respected group of industry leading speakers, this timely conference will provide Updates & ...
(Date:9/1/2015)... September 2, 2015 ... die Forschung und Entwicklung neuartiger Therapien für ... Darmerkrankungen und Reizdarm konzentriert, erhält vom US ... sein neues Medikament patentiert wird. Das Medikament ... bei Kindern verhindert und Entzündungen vorbeugt.   ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... PALO ALTO, Calif. , May 4 "BIO has ... of the biotechnology sector.  It is my goal to build upon these ... fosters the right policy environment for the biobased solutions that our industry ... , , ...
... GENEVA, SWITZERLAND , May 4 /PRNewswire-FirstCall/ - Anavex Life ... from animal studies with ANAVEX 2-73, the company,s lead compound for ... , , ... a new class of drugs that target mitochondrial dysfunction thought to ...
... which have four triangular sides, pack more densely than ... by a collaboration of New York University and Virginia ... series of experiments that involved pouring tetrahedral dice into ... containers were completely filled. After adding water to measure ...
Cached Biology Technology:Statement from Genencor CEO Tjerk de Ruiter Upon Being Elected as Chair of the Industrial & Environmental Section and Board of Directors of the Biotechnology Industry Association (BIO) 2Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 2Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 3Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 4Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 5Densest dice packing and computing with molecules 2
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
(Date:8/18/2015)... , Aug. 17, 2015 Research and ... of the "Global Biometric Authentication & Identification ... Estimation & Forecast, 2015-2020" report to their ... and identification systems market is expected to grow ... to 2020 and generate over $25 billion (approximately) ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
... in 1971 and have become a leading international forum ... and biocatalysis, putting an emphasis on emerging technologies and ... The proposed scope and thrust of the conference will ... developments in fields including protein design and computation, catalytic ...
... - Adrenaline, the hormone that prepares our body to ... molecule switches so fast between several positions, that it ... Jan Steyaert of VIB and the Vrije Universiteit Brussel ... US, have "frozen the molecule in action" using Xaperones, ...
... In the late 1950s, Richard Feynman famously imagined a ... by manipulating matter and creating structures all the way ... over fifty years after "There,s Plenty of Room at ... Angela Belcher, Donald Eigler, and Michael Roukes - are ...
Cached Biology News:Adrenaline receptor 'frozen in action' by VIB researchers 2Scaling up: The future of nanoscience 2Scaling up: The future of nanoscience 3
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: